CL2021000618A1 - Compuesto que contiene oxadiazol y composición farmacéutica que contiene el mismo - Google Patents
Compuesto que contiene oxadiazol y composición farmacéutica que contiene el mismoInfo
- Publication number
- CL2021000618A1 CL2021000618A1 CL2021000618A CL2021000618A CL2021000618A1 CL 2021000618 A1 CL2021000618 A1 CL 2021000618A1 CL 2021000618 A CL2021000618 A CL 2021000618A CL 2021000618 A CL2021000618 A CL 2021000618A CL 2021000618 A1 CL2021000618 A1 CL 2021000618A1
- Authority
- CL
- Chile
- Prior art keywords
- same
- pharmaceutical composition
- oxadiazole
- composition containing
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describe en la presente invención un compuesto de oxadiazol y sales farmacéuticamente útiles del mismo. El compuesto y sales farmacéuticamente útiles del mismo son especialmente adecuadas para el tratamiento de enfermedades del sistema nervioso tal como epilepsia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180113956 | 2018-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021000618A1 true CL2021000618A1 (es) | 2021-08-06 |
Family
ID=69887571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021000618A CL2021000618A1 (es) | 2018-09-21 | 2021-03-12 | Compuesto que contiene oxadiazol y composición farmacéutica que contiene el mismo |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11053208B2 (es) |
| EP (1) | EP3854788A4 (es) |
| JP (1) | JP7430175B2 (es) |
| KR (1) | KR20210047889A (es) |
| CN (1) | CN113272285B (es) |
| AR (1) | AR118413A1 (es) |
| AU (1) | AU2019341357B2 (es) |
| BR (1) | BR112021005269A2 (es) |
| CA (1) | CA3112700A1 (es) |
| CL (1) | CL2021000618A1 (es) |
| IL (1) | IL281553A (es) |
| MX (1) | MX2021003204A (es) |
| TW (1) | TWI826531B (es) |
| WO (1) | WO2020060299A1 (es) |
| ZA (1) | ZA202101520B (es) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US21121A (en) | 1858-08-10 | Appabattjs for purifying gas | ||
| HU182086B (en) | 1979-06-01 | 1983-12-28 | Wellcome Found | Process for preparing new 1,2,4-triazine derivatives |
| GB8412357D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| KR0162036B1 (ko) | 1996-05-31 | 1998-12-01 | 추호석 | 스택커 크래인의 모터 제어장치 및 방법 |
| CA2337795A1 (en) * | 1998-07-08 | 2000-01-20 | Monash University | Pharmaceutical agents |
| UA78211C2 (en) | 2001-07-09 | 2007-03-15 | Ortho Mcneil Pharm Inc | Salts of fructopyranose derivatives as anticonvulsant |
| WO2006017409A2 (en) * | 2004-08-03 | 2006-02-16 | Merck & Co., Inc. | 1,3-disubstituted heteroaryl nmda/nr2b antagonists |
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| US9102622B2 (en) * | 2006-07-28 | 2015-08-11 | University Of Connecticut | Fatty acid amide hydrolase inhibitors |
| JP4503101B2 (ja) | 2008-02-06 | 2010-07-14 | 第一三共株式会社 | 新規フェニルピロール誘導体 |
| NZ600837A (en) | 2009-12-28 | 2014-01-31 | Gen Inc Ass Pharma Valley Project Supporting Organization | 1,3,4-oxadiazole-2-carboxamide compound |
| CN107445919A (zh) * | 2010-03-12 | 2017-12-08 | 奥默罗斯公司 | Pde10抑制剂以及相关组合物和方法 |
| WO2017060488A1 (en) * | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
-
2019
- 2019-09-19 TW TW108133837A patent/TWI826531B/zh active
- 2019-09-20 US US16/613,659 patent/US11053208B2/en active Active
- 2019-09-20 CA CA3112700A patent/CA3112700A1/en active Pending
- 2019-09-20 AR ARP190102667A patent/AR118413A1/es unknown
- 2019-09-20 JP JP2021516367A patent/JP7430175B2/ja active Active
- 2019-09-20 KR KR1020217007242A patent/KR20210047889A/ko not_active Application Discontinuation
- 2019-09-20 MX MX2021003204A patent/MX2021003204A/es unknown
- 2019-09-20 EP EP19863530.2A patent/EP3854788A4/en active Pending
- 2019-09-20 WO PCT/KR2019/012257 patent/WO2020060299A1/ko active Application Filing
- 2019-09-20 BR BR112021005269-0A patent/BR112021005269A2/pt unknown
- 2019-09-20 CN CN201980076515.0A patent/CN113272285B/zh active Active
- 2019-09-20 AU AU2019341357A patent/AU2019341357B2/en active Active
-
2021
- 2021-03-05 ZA ZA2021/01520A patent/ZA202101520B/en unknown
- 2021-03-12 CL CL2021000618A patent/CL2021000618A1/es unknown
- 2021-03-16 IL IL281553A patent/IL281553A/en unknown
- 2021-05-24 US US17/327,928 patent/US11603358B2/en active Active
-
2023
- 2023-01-18 US US18/155,924 patent/US20230150955A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019341357A1 (en) | 2021-04-08 |
| WO2020060299A1 (ko) | 2020-03-26 |
| EP3854788A1 (en) | 2021-07-28 |
| ZA202101520B (en) | 2022-08-31 |
| US20220024886A1 (en) | 2022-01-27 |
| CN113272285B (zh) | 2024-06-07 |
| US20230150955A1 (en) | 2023-05-18 |
| US11603358B2 (en) | 2023-03-14 |
| EP3854788A4 (en) | 2022-06-15 |
| JP7430175B2 (ja) | 2024-02-09 |
| TW202023547A (zh) | 2020-07-01 |
| IL281553A (en) | 2021-05-31 |
| CA3112700A1 (en) | 2020-03-26 |
| AR118413A1 (es) | 2021-10-06 |
| AU2019341357B2 (en) | 2023-03-02 |
| MX2021003204A (es) | 2021-05-27 |
| TWI826531B (zh) | 2023-12-21 |
| KR20210047889A (ko) | 2021-04-30 |
| CN113272285A (zh) | 2021-08-17 |
| US20210115001A1 (en) | 2021-04-22 |
| JP2022503775A (ja) | 2022-01-12 |
| BR112021005269A2 (pt) | 2021-06-15 |
| US11053208B2 (en) | 2021-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| ECSP17002135A (es) | Compuestos antiproliferativos y métodos de uso de los mismos | |
| CO2018011064A2 (es) | Inhibidores de bromodominios | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| ECSP20030074A (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
| SV2017005405A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| DOP2019000193A (es) | Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende | |
| CO2018008846A2 (es) | Derivados de carboxamida útiles como inhibidores de rsk | |
| CY1122968T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο | |
| CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
| BR112016021535A8 (pt) | kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso | |
| UY36003A (es) | Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina. | |
| CL2019000476A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
| CO2017007076A2 (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. | |
| CL2018001631A1 (es) | Compuestos de dihidroquinolinsulfonamida de alquilo | |
| AR104755A1 (es) | Método para el tratamiento de enfermedad neurológica | |
| CL2020001107A1 (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| CL2022003703A1 (es) | Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos | |
| CO2018002428A2 (es) | Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol | |
| AR101901A1 (es) | Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod | |
| AR099558A1 (es) | Régimen de dosaje del compuesto fgf-18 | |
| CL2017002229A1 (es) | Inhibidores de bace1. |